StockUS listing USCHMMFPINKHealthcareEarnings Deterioration

Chimeric Therapeutics Limited(CHMMF) Stock Analysis | Healthcare

USD --+0.00%
Reward46Moderate
Risk68Medium-High
75%Data
Thin -82% profit margin · Revenue down 49% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 4.42M
Reward Ratingⓘ46 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ68 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CHMMF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Chimeric Therapeutics Limited?

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.

AI Brief Pro

The brief on Chimeric Therapeutics Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Chimeric Therapeutics Limited?

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.42M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.485
Insider Activity
12M windowNo data
No insider activity data available for this ticker.